Genotype-Guided Selection of Antiplatelet Therapy: The Evidence Moves East
- PMID: 36898938
- DOI: 10.1016/j.jcin.2023.02.021
Genotype-Guided Selection of Antiplatelet Therapy: The Evidence Moves East
Keywords: CYP2C19 genotype; clopidogrel; percutaneous coronary intervention.
Conflict of interest statement
Funding Support and Author Disclosures Dr Cavallari has received support from Werfen. Dr Franchi has received consulting fees or honoraria from AstraZeneca, Bayer, and Sanofi; and has received institutional payments for grants from PLx Pharma and the Scott R. MacKenzie Foundation.
Comment on
-
Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention.JACC Cardiovasc Interv. 2023 Apr 10;16(7):829-843. doi: 10.1016/j.jcin.2023.01.363. Epub 2023 Mar 8. JACC Cardiovasc Interv. 2023. PMID: 37045504
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources